Oncotarget | The clinical impact of using complex molecular profiling strategies in routine oncology practice https://t.co/4g5V8dDkFR
RT @cathcoste: "Molecular profiling and functional assessment of signalling pathways of advanced solid tumours are becoming increasingly av…
RT @DetiffeOncoDNA: @cathcoste @OncoDNA j'en profite pour vous relayer notre étude sur plus de 1000 patients à travers le monde et qui nous…
RT @cathcoste: "Molecular profiling and functional assessment of signalling pathways of advanced solid tumours are becoming increasingly av…
RT @cathcoste: "Molecular profiling and functional assessment of signalling pathways of advanced solid tumours are becoming increasingly av…
RT @DetiffeOncoDNA: As a founder of OncoDNA, I'm very proud of this first peer reviewed article published by our CSO, JF Laes and colleague…
RT @GregoriGhitti: New publication : https://t.co/fWwIa1DkBj
RT @GregoriGhitti: New publication : https://t.co/fWwIa1DkBj
"Molecular profiling and functional assessment of signalling pathways of advanced solid tumours are becoming increasingly available" https://t.co/EN0U15Br4u via @OncotargetJrnl @OncoDNA #Belgium
@cathcoste @OncoDNA j'en profite pour vous relayer notre étude sur plus de 1000 patients à travers le monde et qui nous a pris 3 ans. On démontre qu'une analyse complète permet d'améliorer l'espérance de vie de patients en échec thérapeutique https://t.co/
RT @DetiffeOncoDNA: As a founder of OncoDNA, I'm very proud of this first peer reviewed article published by our CSO, JF Laes and colleague…
RT @OncoDNA: We are pleased that our first peer reviewed study, published today in Oncotarget, illustrates the effectiveness of OncoDNA’s c…
RT @BioSequence: La revista Oncotarget publica hoy nuestro primer estudio peer reviewed, que demuestra la utilidad de combinar NGS e IHC en…
RT @DetiffeOncoDNA: We are pleased that our first peer reviewed study, published today in Oncotarget, illustrates the effectiveness of Onco…
RT @DetiffeOncoDNA: We are pleased that our first peer reviewed study, published today in Oncotarget, illustrates the effectiveness of Onco…
RT @DetiffeOncoDNA: As a founder of OncoDNA, I'm very proud of this first peer reviewed article published by our CSO, JF Laes and colleague…
La revista Oncotarget publica hoy nuestro primer estudio peer reviewed, que demuestra la utilidad de combinar NGS e IHC en la elección terapéutica de la práctica clínica diaria. Descubre más en el siguiente link: https://t.co/zKUM4Hoyw7
RT @OncoDNA: We are pleased that our first peer reviewed study, published today in Oncotarget, illustrates the effectiveness of OncoDNA’s c…
Great Science is one thing, Big business is another ... But seeing the true benefit of our approach in the real life of advanced cancer patients is definitely above everything ... https://t.co/SmFhEBPSbv
RT @DetiffeOncoDNA: As a founder of OncoDNA, I'm very proud of this first peer reviewed article published by our CSO, JF Laes and colleague…
RT @veleveljkovic: Study performed in 1057 #cancer patients from 13 countries showed that 27% patients treated in accord to complex molecul…
As a founder of OncoDNA, I'm very proud of this first peer reviewed article published by our CSO, JF Laes and colleagues and involving more than 1000 patients in 50 hospitals around the world. Behind the scientific/clinical data co…https://t.co/14AcWFtahw
RT @OncoDNA: We are pleased that our first peer reviewed study, published today in Oncotarget, illustrates the effectiveness of OncoDNA’s c…
Study performed in 1057 #cancer patients from 13 countries showed that 27% patients treated in accord to complex molecular profiling strategy had an overall #survival > 12 months. https://t.co/BpyDc4qbhe Survival rate in control group was not reported.
RT @OncoDNA: We are pleased that our first peer reviewed study, published today in Oncotarget, illustrates the effectiveness of OncoDNA’s c…
RT @OncoDNA: We are pleased that our first peer reviewed study, published today in Oncotarget, illustrates the effectiveness of OncoDNA’s c…
New publication : https://t.co/fWwIa1DkBj
RT @DetiffeOncoDNA: We are pleased that our first peer reviewed study, published today in Oncotarget, illustrates the effectiveness of Onco…
Please here a look here: https://t.co/NYICtHqr3L https://t.co/9XECQmdQ9X
RT @DetiffeOncoDNA: We are pleased that our first peer reviewed study, published today in Oncotarget, illustrates the effectiveness of Onco…
We are pleased that our first peer reviewed study, published today in Oncotarget, illustrates the effectiveness of OncoDNA’s cancer analysis and treatment recommendations in routine clinical practice: https://t.co/no2Al7vVtN https://t.co/3elQ89GYBl
We are pleased that our first peer reviewed study, published today in Oncotarget, illustrates the effectiveness of OncoDNA’s cancer analysis and treatment recommendations in routine clinical practice: https://t.co/wERYv4xuL6 https://t.co/wERYv4xuL6